Drug Profile
MP 3549.1
Alternative Names: MNK010; MP-3549-1; MP-3549.1Latest Information Update: 09 Jun 2016
Price :
$50
*
At a glance
- Originator Mallinckrodt Inc.
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 May 2016 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
- 18 May 2016 No recent reports on development identified - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
- 31 Jul 2013 Phase-I clinical trials in Solid tumours (late-stage disease, second-line therapy or greater) in USA (IV)